Deferasirox治疗铁质积聚疗效怎么样呢？

(Deferasirox, Enrig) is used to treat chronic iron overload caused by frequent blood transfusions (monthly administration of concentrated red blood cells ≥7mL/kg) in patients with beta-thalassemia older than 6 years old. For iron overload caused by children under 6 years old and other transfusion-dependent diseases, the safety and effectiveness data of Deferasirox (Deferasirox, Enrig) in Chinese patients are limited, and it is recommended to use it with caution based on the specific situation of the patient. So, how effective is Deferasirox (Deferasirox, Enrig) ​​in treating iron accumulation?

To analyze the therapeutic effect of Deferasirox (Deferasirox, Enrig) dispersible tablets in the treatment of children with severe β-thalassemia iron overload. Forty-six children with iron overload caused by β-thalassemia major who were treated from October 2015 to October 2017 were selected and divided into the Deferasirox (Deferasirox, Enrig) ​​group and the deferoxamine group according to the random number table method, with 23 cases in each group.

The Deferasirox (Deferasirox, Enrig) group was treated with oral administration of Deferasirox (Deferasirox, Enrig), and the deferoxamine group was treated with subcutaneous pump deferoxamine. The disease control effect after 1 year of treatment, serum iron (SI), ferritin (SF), brain natriuretic peptide (BNP), troponin I (cTnI) and urinary ferritin (UF) levels before and after treatment, liver and heart MRI before and after treatment were compared between the two groups. T2* value and adverse drug reactions. 

Results: The disease control rate in the Deferasirox (Deferasirox, Enrig) group was 100%, which was higher than the 78.26% of the deferoxamine group (Word 2=5.610, P=0.018); after treatment, the serum SI, SF, BNP and cTnI levels of the Deferasirox (Deferasirox, Enrig) group were lower than those of the deferoxamine group, and UF levels, liver and heart MRI The T2 values were all higher than those in the deferoxamine group, and the differences were statistically significant (P<0.05); the incidence of adverse reactions in the Deferasirox (Deferasirox, Enrig) group was lower than that of the deferoxamine group (P<0.05). 

Conclusion: Deferasirox (Deferasirox, Enrig) has a better disease control effect than deferoxamine in the treatment of children with severe β-thalassemia iron overload. It can effectively reduce serum SI, SF, BNP and cTnI levels, reduce the load of iron overload on the liver and heart, and is highly safe.

Common adverse reactions when taking Deferasirox (Deferasirox, Enrig): diarrhea, vomiting, headache, abdominal pain, fever, rash, increased serum creatinine, etc. Other adverse reactions: increased liver enzymes, cough, throat inflammation, urticaria. While taking medicine, patients with thalassemia are often physically weak, so they should live cautiously in daily life, adapt to cold temperatures, and pay attention to preventing external infections; engage in more outdoor activities; breathe fresh air; and perform appropriate physical exercises, Qigong exercises, Tai Chi, etc. to enhance physical fitness and disease resistance.

The above is the content of the treatment effects of (Deferasirox, Enriga), I hope it can help you!